Voyager Therapeutics Future Growth
Future criteria checks 0/6
Voyager Therapeutics's earnings are forecast to decline at 13.4% per annum while its annual revenue is expected to grow at 0.2% per year. EPS is expected to grow by 0.8% per annum. Return on equity is forecast to be -42.4% in 3 years.
Key information
-13.4%
Earnings growth rate
0.8%
EPS growth rate
Biotechs earnings growth | 27.4% |
Revenue growth rate | 0.2% |
Future return on equity | -42.4% |
Analyst coverage | Good |
Last updated | 13 Mar 2025 |
Recent future growth updates
Recent updates
Positive Sentiment Still Eludes Voyager Therapeutics, Inc. (NASDAQ:VYGR) Following 27% Share Price Slump
Feb 25Voyager: Crossing The Blood-Brain Barrier, Competitors, And Investment Relevance
Jan 30Voyager Therapeutics' Tracer Platform Targets CNS Market: Here's Why I'm Neutral
Nov 18Improved Revenues Required Before Voyager Therapeutics, Inc. (NASDAQ:VYGR) Stock's 27% Jump Looks Justified
Oct 17Voyager Therapeutics: CNS Player In Early Stages Of A Turnaround
Aug 26Earnings Beat: Voyager Therapeutics, Inc. (NASDAQ:VYGR) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
Aug 09Lacklustre Performance Is Driving Voyager Therapeutics, Inc.'s (NASDAQ:VYGR) Low P/S
Aug 08Voyager: Alzheimer's Clinical Trial Start (VY-TAU01) Strengthens Investment Thesis
Jun 05There's No Escaping Voyager Therapeutics, Inc.'s (NASDAQ:VYGR) Muted Revenues Despite A 28% Share Price Rise
Mar 15Voyager Therapeutics: A Tortoise With A Shot At Making Gene Therapy Deliver Easier
Mar 08What Does The Future Hold For Voyager Therapeutics, Inc. (NASDAQ:VYGR)? These Analysts Have Been Cutting Their Estimates
Mar 04Voyager Therapeutics, Inc. (NASDAQ:VYGR) Surges 45% Yet Its Low P/S Is No Reason For Excitement
Jan 04Voyager stock rises as Pfizer opts to use AAV capsid for neurologic disease target
Oct 04Voyager Therapeutics hires new finance chief
Sep 07Voyager Therapeutics GAAP EPS of -$0.50 misses by $0.02
Aug 04Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2027 | 73 | -132 | -101 | -73 | 9 |
12/31/2026 | 66 | -117 | -114 | -102 | 12 |
12/31/2025 | 66 | -105 | -104 | -91 | 12 |
12/31/2024 | 80 | -65 | -19 | -15 | N/A |
9/30/2024 | 164 | 26 | -29 | -25 | N/A |
6/30/2024 | 144 | 9 | -22 | -18 | N/A |
3/31/2024 | 119 | -3 | 8 | 13 | N/A |
12/31/2023 | 250 | 132 | 75 | 78 | N/A |
9/30/2023 | 158 | 52 | 86 | 89 | N/A |
6/30/2023 | 195 | 96 | 91 | 94 | N/A |
3/31/2023 | 191 | 99 | 74 | 77 | N/A |
12/31/2022 | 41 | -46 | -15 | -13 | N/A |
9/30/2022 | 71 | -17 | 9 | 11 | N/A |
6/30/2022 | 31 | -60 | 4 | 6 | N/A |
3/31/2022 | 32 | -71 | 1 | 2 | N/A |
12/31/2021 | 37 | -71 | -55 | -54 | N/A |
9/30/2021 | 16 | -93 | -92 | -87 | N/A |
6/30/2021 | 132 | 18 | -100 | -91 | N/A |
3/31/2021 | 160 | 39 | -100 | -89 | N/A |
12/31/2020 | 171 | 37 | -109 | -97 | N/A |
9/30/2020 | 197 | 40 | -110 | -98 | N/A |
6/30/2020 | 100 | -61 | -103 | -95 | N/A |
3/31/2020 | 117 | -41 | -113 | -105 | N/A |
12/31/2019 | 104 | -44 | 41 | 49 | N/A |
9/30/2019 | 74 | -54 | 43 | 48 | N/A |
6/30/2019 | 55 | -59 | 47 | 52 | N/A |
3/31/2019 | 12 | -96 | 57 | 61 | N/A |
12/31/2018 | 8 | -88 | -20 | -16 | N/A |
9/30/2018 | 12 | -78 | N/A | -6 | N/A |
6/30/2018 | 11 | -81 | N/A | -5 | N/A |
3/31/2018 | 10 | -74 | N/A | 2 | N/A |
12/31/2017 | 10 | -71 | N/A | -61 | N/A |
9/30/2017 | 6 | -74 | N/A | -60 | N/A |
6/30/2017 | 8 | -59 | N/A | -54 | N/A |
3/31/2017 | 11 | -50 | N/A | -47 | N/A |
12/31/2016 | 14 | -40 | N/A | -42 | N/A |
9/30/2016 | 17 | -34 | N/A | -39 | N/A |
6/30/2016 | 18 | -32 | N/A | -36 | N/A |
3/31/2016 | 20 | -30 | N/A | -33 | N/A |
12/31/2015 | 17 | -38 | N/A | 41 | N/A |
9/30/2015 | 12 | -35 | N/A | 46 | N/A |
6/30/2015 | 7 | -32 | N/A | 50 | N/A |
3/31/2015 | 3 | -30 | N/A | 55 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: VYGR is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: VYGR is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: VYGR is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: VYGR's revenue (0.2% per year) is forecast to grow slower than the US market (8.5% per year).
High Growth Revenue: VYGR's revenue (0.2% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: VYGR is forecast to be unprofitable in 3 years.
Discover growth companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2025/03/16 01:32 |
End of Day Share Price | 2025/03/14 00:00 |
Earnings | 2024/12/31 |
Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Voyager Therapeutics, Inc. is covered by 27 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Brian Skorney | Baird |
Jack Allen | Baird |
Aydin Huseynov | Benchmark Company |